ES2101317T3 - Medicamento para aumentar el nivel de testosterona. - Google Patents

Medicamento para aumentar el nivel de testosterona.

Info

Publication number
ES2101317T3
ES2101317T3 ES93911730T ES93911730T ES2101317T3 ES 2101317 T3 ES2101317 T3 ES 2101317T3 ES 93911730 T ES93911730 T ES 93911730T ES 93911730 T ES93911730 T ES 93911730T ES 2101317 T3 ES2101317 T3 ES 2101317T3
Authority
ES
Spain
Prior art keywords
medication
increase
testosterone level
testosterone
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93911730T
Other languages
English (en)
Inventor
Claudia Mattern
Rudiger Hacker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arrowdean Ltd
Original Assignee
Arrowdean Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowdean Ltd filed Critical Arrowdean Ltd
Application granted granted Critical
Publication of ES2101317T3 publication Critical patent/ES2101317T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCION SE REFIERE A UN MEDICAMENTO PARA LA ELEVACION DEL NIVEL DE TESTOSTERONA EN SERES HUMANOS CON UN CONTENIDO EN AL MENOS UN PRECURSOR DE TESTOSTERONA.
ES93911730T 1992-05-06 1993-04-30 Medicamento para aumentar el nivel de testosterona. Expired - Lifetime ES2101317T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4214953A DE4214953C2 (de) 1992-05-06 1992-05-06 Arzneimittel zur Erhöhung des Testosteronspiegels

Publications (1)

Publication Number Publication Date
ES2101317T3 true ES2101317T3 (es) 1997-07-01

Family

ID=6458292

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93911730T Expired - Lifetime ES2101317T3 (es) 1992-05-06 1993-04-30 Medicamento para aumentar el nivel de testosterona.

Country Status (7)

Country Link
US (1) US5578588A (es)
EP (1) EP0639077B1 (es)
JP (1) JP3385583B2 (es)
CA (1) CA2118030C (es)
DE (2) DE4214953C2 (es)
ES (1) ES2101317T3 (es)
WO (1) WO1993021924A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4218291A1 (de) * 1992-06-03 1993-12-09 Mattern Et Partner Pharmazeuti Dosierspray für pernasale Applikation
US6117429A (en) * 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
US5880117A (en) * 1998-07-13 1999-03-09 Arnold; Patrick Use of 4-androstenediol to increase testosterone levels in humans
US6391868B2 (en) * 2000-05-10 2002-05-21 Lpt Research, Inc. Use of 5-alpha-androst-1-en-3,17-dione to increase the level of the anabolic/androgenic hormone 17-beta-hydroxy-5-alpha-androst-1-en-3-one in humans
US6242436B1 (en) * 2000-06-15 2001-06-05 William Charles Llewellyn Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans
US20020183532A1 (en) * 2001-06-01 2002-12-05 Roberts William J. Bioavailable prodrugs of androgenic steroids and related method
US20030134828A1 (en) * 2002-01-16 2003-07-17 Roberts William J. Composition and method for increasing in vivo androgen concentration
US6740646B2 (en) 2002-01-16 2004-05-25 Biotest Laboratories, Llc Bioavailable prodrugs of androgenic steroids and related method
US6818668B2 (en) 2002-04-12 2004-11-16 Biotest Laboratories, Llc 5-alkyl-7-alkylcarbonate-isoflavone ester and related method
DE10251028A1 (de) * 2002-11-01 2004-05-19 Jenapharm Gmbh & Co. Kg Verwendung von Progesteron oder einem Progesteronrezeptor-Agonisten zur Hemmung der Steroidsynthese
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
ES2825799T3 (es) 2011-05-13 2021-05-17 Acerus Biopharma Inc Formulaciones en gel de testosterona intranasal de concentración de dosis más baja y uso de las mismas para tratar anorgasmia o trastorno del deseo sexual hipoactivo
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
MX2013013369A (es) 2011-05-15 2014-10-17 Trimel Biopharma Srl Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3284303A (en) * 1963-11-14 1966-11-08 Warner Lambert Pharmaceutical Orally active progesterone compositions
DE3338339A1 (de) * 1982-10-21 1984-04-26 Christopher Harry Dr. London Mortimer Verwendung von dihydrotestosteron-plasmaspiegelsenkern bei der bekaempfung des haarausfalls bei maennern
WO1985002341A1 (en) * 1983-11-30 1985-06-06 Bilton Gerald L Composition for supplemental treatment of male climacteric
US5053403A (en) * 1984-05-11 1991-10-01 Norman Orentreich Methods for treatment of male-pattern baldness
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
NL8801670A (nl) * 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan Farmaceutisch preparaat.

Also Published As

Publication number Publication date
WO1993021924A1 (de) 1993-11-11
CA2118030A1 (en) 1993-11-11
JP3385583B2 (ja) 2003-03-10
EP0639077A1 (de) 1995-02-22
US5578588A (en) 1996-11-26
JPH07508717A (ja) 1995-09-28
DE59305968D1 (de) 1997-04-30
DE4214953A1 (de) 1993-11-11
EP0639077B1 (de) 1997-03-26
CA2118030C (en) 1999-08-31
DE4214953C2 (de) 1995-05-18

Similar Documents

Publication Publication Date Title
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
SV1995000042A (es) Heteroaril-oxazolidinonas de 5 eslabones ref. le a 30523-sv
ES2032860T3 (es) Adsorbatos medicamentosos con surfactante y su preparacion.
ATE211387T1 (de) Oral 1alpha-hydroxyprevitamin d
ES2097155T3 (es) Forma de dosificacion efervescente y metodo de administracion.
ES2024508B3 (es) Forma de dosificacion para liberar un medicamento que comprende un componente regulador de solubilidad.
CL2004000675A1 (es) Uso de una combinacion de androgeno de origen biogenico o sintetico y un estrogeno de origen biogenico o sintetico para preparar un medicamento util en el tratamiento del hipogonadismo y enfermedades hipofisis o glandula pituitaria en hombres, para e
ES2156150T3 (es) Combinacion terapeutica que contiene interferon.
ES2149187T3 (es) Compresa higienica desechable.
ES513357A0 (es) "un sistema terapeutico bajo la forma de un vendaje para administrar el medicamento".
MY102392A (en) Pharmaceutical products providing enhanced analgesia.
AR042262A2 (es) Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
ES2101261T3 (es) Uso de taxol para la fabricacion de un medicamento para el tratamiento del cancer.
ES2032553T3 (es) Dispositivo de cesion transdermica de farmacos con dos mejoradores de permeacion.
ES2080549T3 (es) Medicamentos a base de derivados de polihidroximetileno, procedimiento para su preparacion y empleo.
ES2181165T3 (es) Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas.
SV2002000137A (es) Productos farmaceuticos beta-carbolina ref n. 29342/36539 el
IT1257474B (it) Impiego di inibitori di aromatosi per contraccezione in primati femmine senza influire sul ciclo mestruale
ES2130152T3 (es) Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
AR242907A1 (es) Dispositivo de doble punta para dosificar y suministrar medicamentos.
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
ES2194261T3 (es) Preparaciones de absorcion percutanea estabilizadas.
ES2125356T3 (es) Empleo de leflunomida para la inhibicion de interleuquina 8.
DE3874072D1 (de) Arzneimittel fuer die kombination piperidinoalkanol-dekongestivum.
ES2038642T3 (es) Tratamiento dermico de enfermedades vermiculares del gato con pracicuantel.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 639077

Country of ref document: ES